Ergoteles’s Vor Biopharma VOR Stock Holding History

Ergoteles’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,143	Closed	-$152K	–	1782
2022 Q4	$152K	Sell	1,143 -2,124	-65%	-$210K	0.01%	1146
2022 Q3	$260K	Sell	3,267 -1,054	-24%	-$104K	0.01%	1056
2022 Q2	$430K	Buy	4,321 +3,521	+440%	+$360K	0.01%	905
2022 Q1	$97K	Buy	+800	New	+$136K	﹤0.01%	1127

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Ergoteles's VOR Position: Q1 2023 in Review

Ergoteles sold out of Vor Biopharma (VOR) in Q1 2023, closing a stake of 1,143 shares — an estimated $152K sold.

Ergoteles first reported a position in VOR in Q1 2022 and held it in 4 quarters. The position peaked at $430K in Q2 2022. 59 funds tracked by Wall St. Rank hold VOR as of Q1 2023.

Ergoteles reported no remaining Vor Biopharma position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,143 Vor Biopharma shares in Q1 2023, an estimated $152K.
Ergoteles first reported a position in Vor Biopharma in Q1 2022 and held it in 4 quarters.
Ergoteles's Vor Biopharma position peaked at $430K in Q2 2022.
59 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.